Ashland advances high-growth oral biologics delivery applications with launch of permexa™ sodium caprate
Go back to Ashland advances high-growth oral biologics delivery applications with launch of permexa™ sodium caprate| ASHLAND, Inc. (NYSE: ASH) | Delayed: 69.85 +0.79 (1.14%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $69.06 | 52 Week High | $123.99 | |||
| Open | $70.15 | 52 Week Low | $88.30 | |||
| Day High | $71.10 | P/E | 8.08 | |||
| Day Low | $69.70 | EPS | $8.65 | |||
| Volume | 119,116 | |||||
| ASHLAND, Inc. (NYSE: ASH) | Delayed: 69.85 +0.79 (1.14%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $69.06 | 52 Week High | $123.99 | |||
| Open | $70.15 | 52 Week Low | $88.30 | |||
| Day High | $71.10 | P/E | 8.08 | |||
| Day Low | $69.70 | EPS | $8.65 | |||
| Volume | 119,116 | |||||
